U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C12H13NO4
Molecular Weight 235.2359
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ISO-1

SMILES

COC(=O)CC1CC(=NO1)C2=CC=C(O)C=C2

InChI

InChIKey=AIXMJTYHQHQJLU-UHFFFAOYSA-N
InChI=1S/C12H13NO4/c1-16-12(15)7-10-6-11(13-17-10)8-2-4-9(14)5-3-8/h2-5,10,14H,6-7H2,1H3

HIDE SMILES / InChI

Molecular Formula C12H13NO4
Molecular Weight 235.2359
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/16115897 | https://www.ncbi.nlm.nih.gov/pubmed/20485865 | https://www.ncbi.nlm.nih.gov/pubmed/19592246

ISO-1 inhibits several Macrophage migration inhibitory factor biological activities. The crystal structure of MIF complexed to (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1) reveals that ISO-1 binds to the same position of the active site as p-hydroxyphenylpyruvic acid, a substrate of MIF. ISO-1 demonstrated significant protection from sepsis in vivo. Moreover, ISO-1 treatment led to the significant suppression observed in the inflammatory responses associated with the allergen-induced lung inflammation and fibrosis in murine asthma model. MIF inhibition by ISO-1 may be a potential therapeutic strategy for diabetic nephropathy.

CNS Activity

Curator's Comment: ISO-1, the most tested MIF inhibitor, has already been shown to cross the blood brain barrier.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
7.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Antagonism of macrophage migration inhibitory factor decreases cyclophosphamide cystitis in mice.
2010-11
Macrophage migration inhibitory factor regulates interleukin-6 production by facilitating nuclear factor-kappa B activation during Vibrio vulnificus infection.
2010-10-12
The role of macrophage migration inhibitory factor in Alzheimer's disease.
2010-03
Spinal macrophage migration inhibitory factor contributes to the pathogenesis of inflammatory hyperalgesia in rats.
2010-02
Migratory response of mesenchymal stem cells to macrophage migration inhibitory factor and its antagonist as a function of colony-forming efficiency.
2010-01
ISO-1, a macrophage migration inhibitory factor antagonist, inhibits airway remodeling in a murine model of chronic asthma.
2009-09-16
Small-molecule antagonist of macrophage migration inhibitory factor enhances migratory response of mesenchymal stem cells to bronchial epithelial cells.
2009-09
Novel derivatives of ISO-1 as potent inhibitors of MIF biological function.
2009-08-15
A fluorinated analog of ISO-1 blocks the recognition and biological function of MIF and is orally efficacious in a murine model of colitis.
2009-04-01
Role of macrophage migration inhibitory factor in influenza H5N1 virus pneumonia.
2009
Macrophage migration inhibitory factor promotes colorectal cancer.
2008-10-04
A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells.
2008-09-15
Differential and cell-type specific regulation of responses to Toll-like receptor agonists by ISO-1.
2008-09
Macrophage migration inhibitory factor induces cardiomyocyte apoptosis.
2008-06-27
Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade.
2008-06
Lung-derived macrophage migration inhibitory factor in sepsis induces cardio-circulatory depression.
2007-02
Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells.
2006-12-15
Critical modifications of the ISO-1 scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity.
2006-07-01
ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis.
2005-11-04
Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes.
2005-07
The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents.
2002-07-12
Patents

Sample Use Guides

20 mg/kg total body weight twice a week.
Route of Administration: Intraperitoneal
Macrophages were treated with various concentrations of ISO-1 (10–100 μM) for 30 min. The medium was then replaced with ISO-1-free medium. The cells were then lysed and the tautomerase activity determined. ISO-1 applied to the cell cultures inhibited intracellular tautomerase activity in a dose dependent manner, indicating that the exogenous ISO-1 led to suppression of intracellular MIF tautomerase activity.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:54:35 GMT 2025
Edited
by admin
on Mon Mar 31 21:54:35 GMT 2025
Record UNII
7QFF3Z0V9X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ISO-1
Common Name English
5-ISOXAZOLEACETIC ACID, 4,5-DIHYDRO-3-(4-HYDROXYPHENYL)-, METHYL ESTER
Preferred Name English
Code System Code Type Description
CAS
478336-92-4
Created by admin on Mon Mar 31 21:54:35 GMT 2025 , Edited by admin on Mon Mar 31 21:54:35 GMT 2025
PRIMARY
PUBCHEM
4633677
Created by admin on Mon Mar 31 21:54:35 GMT 2025 , Edited by admin on Mon Mar 31 21:54:35 GMT 2025
PRIMARY
FDA UNII
7QFF3Z0V9X
Created by admin on Mon Mar 31 21:54:35 GMT 2025 , Edited by admin on Mon Mar 31 21:54:35 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY